iPROSPECT (Irish PROgramme for Stratified ProstatE Cancer Therapy)

iPROSPECT was established in 2014 with funding from the Irish Cancer Society in partnership with Movember.  iPROSPECT consists of connected and supported projects, all of which are integrated to bring about a transformation from current practice to a more individual and personalised treatment of patients with metastatic prostate cancer in order to improve patient outcomes.

The iPROSPECT team is led by the triumvirate leadership of Dr Ray McDermott (TCD), Prof Stephen Finn (TCD) and Prof William Watson (UCD). Principal Investigators on the first series of projects are Dr Sharon Glynn (NUIG), Prof Stephen Finn (TCD) and Dr Antoinette Perry (TCD).

The team are all members of the National Prostate Cancer Research Consortium (NPCRC), established in 2011 to bring together like-minded scientists, clinicians, epidemiologists, health economists, statisticians, research nurses and allied healthcare professional from the academic research institutes of TCD, NUI-Galway, UCD, UCC, DCU and RCSI and the well-established organisations All Ireland Cooperative Oncology Research Group (ICORG), the National Cancer Registry, Ireland (NCRI) and the National Centre for Pharmacoeconomics (NCPE).


Dr Ray McDermot

PI and Clinical Director

Prof Stephen Finn

Translational Director

Prof William Watson

Scientific Director

Translational Study

The translational study is being implemented by ICORG in hospitals across Ireland including: Tallaght Hospital (AMNCH), St Vincent’s University Hospital, St Vincent’s Private Hospital, The Beacon Hospital, St. James’s Hospital, Cork University Hospital, Mater Misericordiae University Hospital, Mater Private Hospital, Beaumont Hospital, Sligo General Hospital, and Waterford Regional Hospital.

The study currently has 2 cohorts of patients:

Cohort 1 (recruitment now complete):  patients with metastatic prostate cancer who have commenced or are about to commence androgen-deprivation therapy (ADT)

Cohort 2 (recruitment open):  patients with castrate-resistant metastatic prostate cancer.

In addition to routine biospecimen collection, e.g. bloods for clinical chemistry and haematology, more in-depth monitoring on a genomic, epigenomic and proteomic scale will be performed to delineate factors which may aid stratification of patients for treatment. Analysis will be performed primarily within patient with measurements taken at baseline, before each new treatment is commenced and regularly during treatment. This longitudinal study will investigate how clinical and biological patterns change over time and relate to each individual’s treatment response and progression of disease. See table below for biospecimen and data types collected.

 BaselineEvery 4 monthsOptional study
Circulating Tumour Cells (from Blood)  
Archival Prostate Tumour Tissue   
Metastatic Tumour Tissue   
Bone Marrow Tissue/Aspirate   
Quality of Life Questionnaires (PCRC lifestyle, FACT-P, Brief Pain Inventory- Short form)

For more information about iPROSPECT, contact Ray.McDermott@tuh.ie